Findings from RAPTOR suggest 5-year biochemical recurrence may be a good indication of prostate cancer cure status. Biochemical recurrence within 5 years of treating prostate cancer with radiotherapy ...

"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS. Stereotactic body radiotherapy (SBRT) may provide the best ...

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer. The data from the phase 3 GETUG trial, ...

Zaorsky discusses his team's ASTRO 2024 abstract showing clear benefit of radiotherapy and ablation in reduced kidney effects in patients with RCC. Stereotactic body radiotherapy (SBRT), partial ...

The estimated 10-year cumulative incidence of PCSM was 1.2% for those who did not experience biochemical recurrence within 5 years of radiotherapy vs 29.0% among those who did. Biochemical recurrence ...

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic ...

“Pembrolizumab maintenance therapy after SABR boost to bladder tumor and concurrent radio-chemotherapy was well tolerated with promising efficacy in the early analysis," said Shang-bin Qin, MD.

Video content above is prompted by the following question: What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment? How can these ...

The panelist discusses how incorporating chemotherapy into combination treatments for metastatic prostate cancer presents challenges such as increased resource requirements, the need for ...

"When determining which code you should use, you must consider your Medicare carrier’s published rules and commercial payer processing policies," write Jonathan Rubenstein, MD, and Mark Painter. The ...

"Patient-reported satisfaction scores were high for both telehealth and inpatient visits for both new and established encounters," says Daniel Carson, MD, MS. In this video, Daniel Carson, MD, MS, ...

Neal Shore, MD, FACS, discusses the progress of a 65-year-old patient with mCRPC through various treatments and evaluation for Lutetium-177 therapy based on his PSMA PET scan and MRI.